A Multi-center, Prospective, Randomized Study to Evaluate the Usefulness of Applying the Chronic Side Effect Management Platform (Wecare) in Gastric Cancer Survivors

The KOrean QUality of life in Stomach cancer patients Study group (KOQUSS) made a method (KOQUSS-40) for assessing appropriately the quality of life of gastric cancer patients who have undergone gastrectomy, and developed a digital platform (Wecare) based on KOQUSS-40. In this study, we propose a randomized controlled trial to compare quality of life after gastrectomy in patients with and without smartphone app support.

开始日期2024-04-01

申办/合作机构

Gyeongsang National University Hospital

[+1]

NCT06104033 / RecruitingN/AIIT

Practice Change With Drug-coated Balloon in Patients With multiVessel Coronary Artery Disease

This study is a prospective, multicenter, open-label, observational study to investigate the impact of using drug-coated balloons (DCBs) in the treatment of coronary artery lesions in patients with multivessel coronary artery disease (MVD), as opposed to the default strategy of using only drug-eluting stents (DES). The investigators aim to assess changes in clinical practice towards a hybrid treatment strategy (DES and DCB) and its effects on clinical outcomes.

开始日期2023-09-18

申办/合作机构

Seoul National University Hospital

[+21]

NCT05978882 / Not yet recruitingN/AIIT

Feasibility Study of Sentinel Navigation Surgery in Early Gastric Cancer Using Fluorescence (SENORITA4 Trial)

SENORITA 1 trial showed laparoscopic sentinel lymph node biopsy and stomach preserving surgery in early gastric cancer can increase the quality of life. (Ryu KW et al. JCO 2022) The radioactive isotope is difficult to use because of the hazard of radiation and shortage of materials. The aim of this study is to investigate whether laparoscopic sentinel lymph node biopsy and stomach-preserving surgery using only fluorescence is feasible.

开始日期2023-08-17

申办/合作机构

National Cancer Center Korea

[+7]

100 项与 Gyeongsang National University Hospital 相关的临床结果

登录后查看更多信息

0 项与 Gyeongsang National University Hospital 相关的专利（医药）

登录后查看更多信息

1,876

项与 Gyeongsang National University Hospital 相关的文献（医药）

2024-10-01·Gastrointestinal Endoscopy

Impact of the suprapapillary method on patency in distal malignant biliary obstruction: a multicenter randomized controlled trial

Article

作者: Ko, Sung Woo ; Kim, Seongje ; Joo, Hyun Don ; Choi, Seong Ji ; Oh, Dongwook ; Seo, Dong-Wan ; Song, Tae Jun ; Yoon, Jai Hoon ; Lee, Sung Koo ; Oh, Chi Hyuk ; Yoon, Seung Bae ; Park, Jin-Seok

BACKGROUND AND AIMSPlacement of a self-expandable metal stent (SEMS) across the duodenal major papilla carries a risk of duodenobiliary reflux (DBR). The suprapapillary method of stent placement may reduce DBR and improve stent patency compared with the transpapillary method. This study compared the clinical outcomes between the suprapapillary and transpapillary methods for distal malignant biliary obstruction (DMBO).METHODSBetween January 2021 and January 2023, consecutive patients with DMBO from 6 centers in South Korea were randomly assigned to either the suprapapillary arm or transpapillary method arm in a 1:1 ratio. The primary outcome was the duration of stent patency, and secondary outcomes were the cause of stent dysfunction, adverse events, and overall survival rate.RESULTSEighty-four patients were equally assigned to each group. The most common cause of DMBO was pancreatic cancer (50, 59.5%), followed by bile duct (20, 23.8%), gallbladder (11, 13.1%), and other cancers (3, 3.6%). Stent patency was significantly longer in the suprapapillary group (median, 369 days [interquartile range, 289-497] vs 154 days [interquartile range, 78-361]; P < .01). Development of DBR was significantly lower in the suprapapillary group (9.4% vs 40.8%, P < .01). Adverse events and overall survival rate were not significantly different between the 2 groups.CONCLUSIONSThe placement of SEMSs using the suprapapillary method resulted in a significantly longer duration of stent patency. It is advisable to place the SEMS using the suprapapillary method in DMBO. Further studies with a larger number of patients are required to validate the benefits of the suprapapillary method. (Clinical trial registration number: KCT0005572.).

2024-10-01·ESMO Open

Nationwide precision oncology pilot study: KOrean Precision Medicine Networking Group Study of MOlecular profiling-guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) KCSG AL-20-05

Article

作者: Han, S W ; Yoon, S. ; Hwang, I G ; Zang, D Y ; Jung, H.A. ; Lee, Y-G ; Choi, Y.J. ; Kim, T M ; Kim, S Y ; Kim, S.Y. ; Lee, S.-H. ; Kang, J.H. ; Lee, G.-W. ; Yun, H ; Choi, Y J ; Lee, S-H ; Cha, Y. ; Choi, Y L ; Lee, Y.-G. ; Jung, H A ; Lee, S. ; Yun, H. ; Kang, J H ; Kim, T.-Y. ; Choi, Y.L. ; Yoon, S ; Hwang, I.G. ; Han, S.W. ; Zang, D.Y. ; Kim, T.W. ; Cha, Y ; Kim, J.H. ; Kim, T-Y ; Kim, T W ; Kim, J H ; Lee, G-W ; Lee, S ; Kim, T.M.

BACKGROUNDNext-generation sequencing (NGS) has become widely available but molecular profiling-guided therapy (MGT) had not been well established in the real world due to lack of available therapies and expertise to match treatment. Our study was designed to test the feasibility of a nationwide platform of NGS-guided MGT recommended by a central molecular tumor board (cMTB) for metastatic solid tumors.PATIENTS AND METHODSPatients with advanced or metastatic solid tumors with available NGS results and without standard treatment were enrolled. The cMTB interpreted the patients' NGS reports and recommended the following: (i) investigational medicinal products (IMPs) approved in other indications; (ii) alternative treatments; (iii) clinical trials. The primary variables were the proportion of patients with actionable genomic alterations and those receiving MGT as per cMTB recommendations. Others included treatment duration (TD), overall response rate (ORR), disease control rate (DCR), and safety.RESULTSFrom February 2021 to February 2022, 193 cases [99 (51.3%) men; median age 58 years (range 24-88 years); median line of previous treatment 3 (range 0-9)] from 29 sites were enrolled for 60 cMTB sessions. The median time from case submission to cMTB discussion was 7 days (range 2-20 days), and to IMP treatment initiation was 28 days (range 14-90 days). Actionable genetic alterations were found in 145 patients (75.1%). A total of 89 (46.1%) patients received actual dosing of IMPs, and 10 (5.2%) were enrolled in cMTB-recommended clinical trials, achieving an MGT rate of 51.3%. ORR and DCR of IMPs were 10.1% and 72.5%, respectively. The median TD was 3.5 months [95% confidence interval (CI) 2.8-5.5 months], and the 4-month TD rate was 44.9%. The median overall survival of patients who received IMPs was 6.9 months (95% CI 5.2-10.0 months).CONCLUSIONKOSMOS confirmed the feasibility of MGT recommended by the cMTB, achieving a high MGT match rate and promising effectiveness in heavily pretreated advanced cancer patients.

2024-09-27·Journal of Chest Surgery

Ultrasound-Guided Percutaneous Tracheostomy in Cardiovascular and Thoracic Surgery of South Korea: Retrospective Evaluation of Efficacy and Safety in Critically Ill Patients

Article

作者: Lee, Young Hyun ; Park, Hyun Oh ; Kang, Dong Hoon

BackgroundIn intensive care settings, the maintenance of ventilation is typically essential. Tracheostomy is frequently performed to facilitate long-term ventilation and to minimize associated complications. This procedure can be conducted using several techniques, including traditional surgery, endoscopic approaches, and ultrasound-guided methods.MethodsWe retrospectively examined data from all patients admitted to the intensive care unit of our institution who underwent ultrasound-guided percutaneous tracheostomy (UPCT) between March 2018 and April 2023. The study included a total of 81 patients aged 15 years or older. To assess the incidence of complications, we classified these issues as either minor or major, with major complications encompassing events such as bleeding necessitating blood transfusion.ResultsThe most frequent minor complication was bleeding that did not require blood transfusion, which occurred in 15 patients (18.5%). Major complications were identified in 7 patients (8.6%), all of whom experienced bleeding that necessitated transfusion. However, we noted no cases of infection, conversion to open surgery, or tracheal stenosis surgery. The complication rate did not significantly differ from those reported in previous studies.ConclusionThese results indicate that UPCT can be safely used in critically ill patients, although further research on this topic is needed.

100 项与 Gyeongsang National University Hospital 相关的药物交易

登录后查看更多信息

100 项与 Gyeongsang National University Hospital 相关的转化医学

登录后查看更多信息